Physician profile
Tin M Way
NPI 1396711917
$1,319.19
in general payments reported to CMS, 2019-2025
12 companies · $165 in 2025
The $165 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $371 · 2022: $248 · 2023: $37.94 · 2024: $497 · 2025: $165.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $700.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $699.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $420.30 | 2021-2025 | Impella |
| Edwards Lifesciences Corporation | $188.95 | 2024 | Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $131.72 | 2021 | |
| Boston Scientific Corporation | $121.01 | 2021-2023 | Synergy |
| E.R. Squibb & Sons, L.L.C. | $115.88 | 2024 | Camzyos |
| Inari Medical, INC. | $103.80 | 2022 | |
| Medtronic, INC. | $63.33 | 2021 | |
| Abbott Laboratories | $58.92 | 2022-2023 | 2nd Gen Centrimag Primary Console |
| Heartflow, INC. | $45.65 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $26.86 | 2024 | Lifevest |
| Amgen INC. | $25.28 | 2024 | Repatha |
| Cordis US Corp. | $17.49 | 2025 | Infiniti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tin Way listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.